Terms: = Leukemia AND ABCG2, ABC15, ABCP, BCRP, BCRP1, BMDP, CD338, CDw338, EST157481, GOUT1, MRX, MXR, MXR-1, MXR1, UAQTL1 AND Treatment
175 results:
1. Increased Anti-Inflammatory Therapeutic Potential and Progenitor Marker Expression of Corneal Mesenchymal Stem Cells Cultured in an Optimized Propagation Medium.
Hopkinson A; Notara M; Cursiefen C; Sidney LE
Cell Transplant; 2024; 33():9636897241241992. PubMed ID: 38602231
[TBL] [Abstract] [Full Text] [Related]
2. ABC transporters are predictors of treatment failure in acute myeloid leukaemia.
Cerovska E; Salek C; Kundrat D; Sestakova S; Pesek A; Brozinova I; Belickova M; Remesova H
Biomed Pharmacother; 2024 Jan; 170():115930. PubMed ID: 38039756
[TBL] [Abstract] [Full Text] [Related]
3. Constitutively Synergistic Multiagent Drug Formulations Targeting MERTK, FLT3, and BCL-2 for treatment of AML.
Kelvin JM; Jain J; Thapa A; Qui M; Birnbaum LA; Moore SG; Zecca H; Summers RJ; Switchenko JM; Costanza E; Uricoli B; Wang X; Jui NT; Fu H; Du Y; DeRyckere D; Graham DK; Dreaden EC
Pharm Res; 2023 Sep; 40(9):2133-2146. PubMed ID: 37704893
[TBL] [Abstract] [Full Text] [Related]
4. Population pharmacokinetics and pharmacogenetics analyses of imatinib in Chinese patients with chronic myeloid leukemia in a real-world situation.
He S; Shao Q; Zhao J; Bian J; Zhao Y; Hao X; Li Y; Hu L; Liu B; He H; Huang L; Jiang Q
Cancer Chemother Pharmacol; 2023 Nov; 92(5):399-410. PubMed ID: 37624393
[TBL] [Abstract] [Full Text] [Related]
5. Development of constitutively synergistic nanoformulations to enhance chemosensitivity in T-cell leukemia.
Kelvin JM; Chimenti ML; Zhang DY; Williams EK; Moore SG; Humber GM; Baxter TA; Birnbaum LA; Qui M; Zecca H; Thapa A; Jain J; Jui NT; Wang X; Fu H; Du Y; Kemp ML; Lam WA; Graham DK; DeRyckere D; Dreaden EC
J Control Release; 2023 Sep; 361():470-482. PubMed ID: 37543290
[TBL] [Abstract] [Full Text] [Related]
6. The cardiac glycoside ZINC253504760 induces parthanatos-type cell death and G2/M arrest via downregulation of MEK1/2 phosphorylation in leukemia cells.
Zhou M; Boulos JC; Klauck SM; Efferth T
Cell Biol Toxicol; 2023 Dec; 39(6):2971-2997. PubMed ID: 37322258
[TBL] [Abstract] [Full Text] [Related]
7. Impact of
Dalle Fratte C; Polesel J; Gagno S; Posocco B; De Mattia E; Roncato R; Orleni M; Puglisi F; Guardascione M; Buonadonna A; Toffoli G; Cecchin E
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834713
[TBL] [Abstract] [Full Text] [Related]
8. Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape.
Solana-Altabella A; Megías-Vericat JE; Ballesta-López O; Martínez-Cuadrón D; Montesinos P
Expert Rev Clin Pharmacol; 2023 Feb; 16(2):133-148. PubMed ID: 36708283
[TBL] [Abstract] [Full Text] [Related]
9. Association of ABCB1, abcg2 drug transporter polymorphisms and smoking with disease risk and cytogenetic response to imatinib in chronic myeloid leukemia patients.
Mohammadi F; Rostami G; Hamid M; Shafiei M; Azizi M; Bahmani H
Leuk Res; 2023 Mar; 126():107021. PubMed ID: 36696828
[TBL] [Abstract] [Full Text] [Related]
10. Shenqi Fuzheng injection reverses M2 macrophage-mediated cisplatin resistance through the PI3K pathway in breast cancer.
Yan B; Shi R; Lu YY; Fang DD; Ye MN; Zhou QM
PLoS One; 2023; 18(1):e0279752. PubMed ID: 36693064
[TBL] [Abstract] [Full Text] [Related]
11. A Study to Explore the Role of IDH1 (R132) Mutation on Imatinib Toxicity and Effect of abcg2/OCT1 Expression on N-Desmethyl Imatinib Plasma Level in Egyptian Chronic Myeloid leukemia Patients.
Sabri A; Omran MM; Azim SA; Abdelfattah R; Allam RM; Shouman SA
Drug Res (Stuttg); 2023 Mar; 73(3):146-155. PubMed ID: 36630991
[TBL] [Abstract] [Full Text] [Related]
12. Effects of splicing-regulatory polymorphisms in ABCC2, abcg2, and ABCB1 on methotrexate exposure in Chinese children with acute lymphoblastic leukemia.
Li M; Kong XY; Wang SM
Cancer Chemother Pharmacol; 2023 Jan; 91(1):77-87. PubMed ID: 36463535
[TBL] [Abstract] [Full Text] [Related]
13. The WD repeat-containing protein 5 (WDR5) antagonist WDR5-0103 restores the efficacy of cytotoxic drugs in multidrug-resistant cancer cells overexpressing ABCB1 or abcg2.
Wu CP; Hsieh YJ; Tseng HY; Huang YH; Li YQ; Hung TH; Wang SP; Wu YS
Biomed Pharmacother; 2022 Oct; 154():113663. PubMed ID: 36081287
[TBL] [Abstract] [Full Text] [Related]
14. Genetic Variants of ABC and SLC Transporter Genes and Chronic Myeloid Leukaemia: Impact on Susceptibility and Prognosis.
Alves R; Gonçalves AC; Jorge J; Marques G; Ribeiro AB; Tenreiro R; Coucelo M; Diamond J; Oliveiros B; Pereira A; Freitas-Tavares P; Almeida AM; Sarmento-Ribeiro AB
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077209
[TBL] [Abstract] [Full Text] [Related]
15. Biomarker LEPRE1 induces pelitinib-specific drug responsiveness by regulating abcg2 expression and tumor transition states in human leukemia and lung cancer.
Lee AR; Lee S; Shin JY; Kim JY; Moon KS; Jung J
Sci Rep; 2022 Feb; 12(1):2928. PubMed ID: 35190588
[TBL] [Abstract] [Full Text] [Related]
16. Pharmacogenetics of induction therapy-related toxicities in childhood acute lymphoblastic leukemia patients treated with UKALL 2003 protocol.
Aslam S; Ameer S; Shabana NA; Ahmed M
Sci Rep; 2021 Dec; 11(1):23757. PubMed ID: 34887513
[TBL] [Abstract] [Full Text] [Related]
17. Multiplex Single-Cell Analysis of Cancer Cells Enables Unbiased Uncovering Subsets Associated with Cancer Relapse: Heterogeneity of Multidrug Resistance in Precursor B-ALL.
Zhou Y; Wai-Choi Tse E; Leung R; Cheung E; Li H; Sun H
ChemMedChem; 2022 Feb; 17(3):e202100638. PubMed ID: 34783169
[TBL] [Abstract] [Full Text] [Related]
18. Piceatannol, a Structural Analog of Resveratrol, Is an Apoptosis Inducer and a Multidrug Resistance Modulator in HL-60 Human Acute Myeloid leukemia Cells.
Siedlecka-Kroplewska K; Wrońska A; Kmieć Z
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638937
[TBL] [Abstract] [Full Text] [Related]
19. Assessment of Transporter-Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients With Relapse or Refractory Acute Myeloid leukemia or Myelodysplastic Syndrome.
Cheng Y; Wang X; Tong Z; Reyes J; Carayannopoulos L; Zhou S; Li Y
J Clin Pharmacol; 2022 Apr; 62(4):494-504. PubMed ID: 34617279
[TBL] [Abstract] [Full Text] [Related]
20. Genetic factors in treatment-related cardiovascular complications in survivors of childhood acute lymphoblastic leukemia.
Petrykey K; Rezgui AM; Guern ML; Beaulieu P; St-Onge P; Drouin S; Bertout L; Wang F; Baedke JL; Yasui Y; Hudson MM; Raboisson MJ; Laverdière C; Sinnett D; Andelfinger GU; Krajinovic M
Pharmacogenomics; 2021 Sep; 22(14):885-901. PubMed ID: 34505544
[No Abstract] [Full Text] [Related]
[Next]
